What does this research mean for the field?

Cilostazol may improve prognosis in patients with diabetes and lower extremity peripheral arterial disease without increasing bleeding risk. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Investigate the impact of cilostazol on prognosis in diabetic patients with lower extremity peripheral arterial disease (PAD).

January 10, 2026Atherosclerosis1 citationsOpen Access

View Full Paper

Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study

SMS. Moon SHSangmo Hong KHKyungdo Han

Key Result

Cilostazol may improve prognosis in patients with diabetes and lower extremity PAD without increasing bleeding risk.

Key Points

Investigate the impact of cilostazol on prognosis in diabetic patients with lower extremity peripheral arterial disease (PAD).
Nationwide population-based study
Analyzed data from patients with diabetes and lower extremity PAD
Compared prognosis with and without cilostazol treatment
Cilostazol improves prognosis in diabetic patients with PAD
No significant increase in bleeding risk was observed
Epidemiological evidence suggests better outcomes for this patient group

Structured PICO

Does cilostazol improve the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus?

Population

Patients with diabetes mellitus and lower extremity peripheral arterial disease in Korea

Intervention

Cilostazol

Outcome

Prognosis of lower extremity peripheral arterial disease

Cilostazol may improve outcomes in patients with diabetes and lower extremity PAD without increasing bleeding risk.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

In patients with diabetes and lower extremity PAD, cilostazol may improve the prognosis without increasing the risk of bleeding. These findings provide epidemiological evidence for better PAD outcomes in patients with diabetes, although further research is required to elucidate the underlying mechanisms.

问 AI

Bookmark

View Full Paper

Cite This Study

Moon et al. (Mon,) reported a other. Cilostazol may improve prognosis in patients with diabetes and lower extremity PAD without increasing bleeding risk.

synapsesocial.com/papers/6963221491e05aa366cb889b https://doi.org/https://doi.org/10.1016/j.atherosclerosis.2025.120634

问 AI

Bookmark

View Full Paper